溶栓素

Thrombolysin is an enzyme that catalyzes the breakdown of blood clots, also known as thrombolytic agent.
血栓溶酶是一种催化血块分解的酶，也被称为溶栓剂。
The administration of thrombolysin within four hours of a stroke onset can significantly improve patient outcomes.
中风发生后四小时内使用血栓溶酶可显著改善患者预后。
In the treatment of myocardial infarction, thrombolysin is often used to dissolve the obstructive clot in coronary arteries.
在心肌梗死的治疗中，血栓溶酶常被用于溶解冠状动脉中的阻塞性血栓。
Researchers are investigating new methods to enhance the efficacy and safety profile of thrombolysin for thrombolytic therapy.
研究人员正在研究新方法以提高血栓溶酶在溶栓疗法中的有效性和安全性。
A combination of thrombolysin with antiplatelet drugs can further reduce the risk of recurrent thrombotic events.
血栓溶酶与抗血小板药物联合使用可以进一步降低血栓复发的风险。
The use of thrombolysin requires careful monitoring due to the potential for severe bleeding complications.
使用血栓溶酶需要谨慎监控，因为它有可能导致严重的出血并发症。
Thrombolysin has been shown to have a significant role in the early management of deep vein thrombosis.
血栓溶酶已被证实对于深静脉血栓形成的早期管理具有重要作用。
Patients with a history of bleeding disorders should not be prescribed thrombolysin unless absolutely necessary.
有出血性疾病病史的患者除非绝对必要，否则不应开具血栓溶酶处方。
The development of thrombolysin resistance is a growing concern in patients undergoing repeated thrombolytic treatments.
对于接受多次溶栓治疗的患者来说，产生血栓溶酶耐药性是一个日益严重的问题。
Thrombolysin therapy should only be initiated under the supervision of a healthcare professional familiar with its indications and contraindications.
血栓溶酶疗法只能在熟悉其适应症和禁忌症的医疗专业人员指导下启动。